Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026)
Ardelyx (ARDX) reported Total Non-Current Liabilities of $330.0 million for Q1 2026, up 38.67% on a YoY basis from $238.0 million in Q1 2025, and up 6.88% quarter-over-quarter from $308.8 million in Q4 2025.
Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx has reported Total Non-Current Liabilities for 14 years, with the latest figure at $330.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 38.67% year-over-year to $330.0 million; the trailing twelve-month figure through Mar 2026 stood at $330.0 million (up 38.67% YoY), and the FY2025 full-year result was $308.8 million, up 30.32% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $330.0 million, up from $308.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $330.0 million in Q1 2026, with the low at $67.4 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $176.5 million across 5 years, with a median of $171.5 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities rose 19.6% — and 2024, when it soared 120.19%.
- Ardelyx's Total Non-Current Liabilities stood at $80.5 million in 2022, then jumped by 37.4% to $110.6 million in 2023, then soared by 114.26% to $236.9 million in 2024, then soared by 30.32% to $308.8 million in 2025, then climbed by 6.88% to $330.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $330.0 million (Q1 2026), $308.8 million (Q4 2025), and $303.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 330.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 330.02 Mn |
| Dec 31, 2025 | 308.78 Mn |
| Sep 30, 2025 | 303.26 Mn |
| Jun 30, 2025 | 299.48 Mn |
| Mar 31, 2025 | 238.00 Mn |
| Dec 31, 2024 | 236.94 Mn |
| Sep 30, 2024 | 185.19 Mn |
| Jun 30, 2024 | 173.39 Mn |
| Mar 31, 2024 | 169.61 Mn |
| Dec 31, 2023 | 110.58 Mn |
| Sep 30, 2023 | 84.11 Mn |
| Jun 30, 2023 | 87.87 Mn |
| Mar 31, 2023 | 79.38 Mn |
| Dec 31, 2022 | 80.48 Mn |
| Sep 30, 2022 | 67.39 Mn |
| Jun 30, 2022 | 68.98 Mn |
| Dec 31, 2021 | 67.30 Mn |
| Dec 31, 2020 | 74.07 Mn |
| Sep 30, 2020 | 65.96 Mn |
| Jun 30, 2020 | 69.87 Mn |